"Oxazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-membered heterocycles containing an oxygen and a nitrogen.
| Descriptor ID |
D010078
|
| MeSH Number(s) |
D03.383.533
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oxazines".
Below are MeSH descriptors whose meaning is more specific than "Oxazines".
This graph shows the total number of publications written about "Oxazines" by people in this website by year, and whether "Oxazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 2 | 3 |
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oxazines" by people in Profiles.
-
Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV. AIDS. 2026 May 01; 40(5):600-610.
-
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20?years in sub-Saharan Africa. Contemp Clin Trials. 2025 Aug; 155:107963.
-
An audit of the HIV drug resistance testing program in Malawi. Malawi Med J. 2025 Mar; 37(1):16-22.
-
Dolutegravir-induced neural tube defects in mice are folate responsive. AIDS. 2024 03 15; 38(4):439-446.
-
Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan. BMC Pediatr. 2023 01 21; 23(1):35.
-
Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents. Clin Infect Dis. 2021 08 02; 73(3):e580-e586.
-
Rapid initiation of dolutegravir for adults in Botswana. Lancet HIV. 2020 08; 7(8):e523-e524.
-
Spectral Characterization of Stem Cell-Derived Myelination within the Injured Adult PNS Using the Solvatochromic Dye Nile Red. Cells. 2020 01 11; 9(1).
-
The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid. AIDS. 2019 11 01; 33(13):1967-1976.
-
CYP1A1 and 1B1-mediated metabolic pathways of dolutegravir, an HIV integrase inhibitor. Biochem Pharmacol. 2018 12; 158:174-184.